VEGF-B Activators belong to a specialized class of chemical compounds designed to modulate the activity of vascular endothelial growth factor B (VEGF-B). VEGF-B is a member of the vascular endothelial growth factor (VEGF) family, a group of signaling proteins that play essential roles in angiogenesis, the process of blood vessel formation. Unlike some other VEGF family members that are well-known for their roles in promoting angiogenesis, VEGF-B has distinct functions and is primarily associated with regulating vascular stability and metabolic homeostasis. VEGF-B is produced as a proprotein that undergoes proteolytic cleavage to generate bioactive forms.
VEGF-B Activators are compounds designed to specifically interact with VEGF-B and influence its signaling pathways. These activators can modulate VEGF-B activity either by enhancing or inhibiting its effects, depending on their chemical structure and mode of action. By targeting VEGF-B, these compounds have the ability to affect processes related to vascular biology, such as vessel permeability and maintenance. Although VEGF-B's precise mechanisms and functions are still being elucidated, it has been suggested to have a role in cardiac and skeletal muscle metabolism, making it an interesting subject for research in the context of cardiovascular and metabolic diseases. The study of VEGF-B Activators provides valuable insights into the intricate regulatory mechanisms of angiogenesis and vascular stability beyond the well-established functions of other VEGF family members. Researchers continue to explore the mechanisms of VEGF-B activation and its implications in various physiological processes to better understand its unique roles in vascular biology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rosiglitazone | 122320-73-4 | sc-202795 sc-202795A sc-202795C sc-202795D sc-202795B | 25 mg 100 mg 500 mg 1 g 5 g | $118.00 $320.00 $622.00 $928.00 $1234.00 | 38 | |
A PPARγ agonist that can enhance VEGF-B expression as part of its angiogenic and vasodilatory effects. | ||||||
Pioglitazone | 111025-46-8 | sc-202289 sc-202289A | 1 mg 5 mg | $54.00 $123.00 | 13 | |
Another PPARγ agonist, known to upregulate VEGF-B expression, contributing to angiogenesis. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $40.00 | 9 | |
Activates PPARα and may indirectly increase VEGF-B levels, influencing vascular growth. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Known for its anti-angiogenic properties, it can paradoxically upregulate VEGF-B under certain conditions. | ||||||
β-Estradiol | 50-28-2 | sc-204431 sc-204431A | 500 mg 5 g | $62.00 $178.00 | 8 | |
A form of estrogen that can increase VEGF-B expression, potentially influencing angiogenesis. | ||||||
Vildagliptin | 274901-16-5 | sc-208485 | 10 mg | $173.00 | 4 | |
A DPP-4 inhibitor, shown to upregulate VEGF-B in certain contexts, affecting vascular dynamics. | ||||||
β-Nicotinamide mononucleotide | 1094-61-7 | sc-212376 sc-212376A sc-212376B sc-212376C sc-212376D | 25 mg 100 mg 1 g 2 g 5 g | $92.00 $269.00 $337.00 $510.00 $969.00 | 4 | |
Involved in NAD+ biosynthesis, can indirectly affect VEGF-B levels through energy metabolism pathways. | ||||||
hydroxychloroquine | 118-42-3 | sc-507426 | 5 g | $56.00 | 1 | |
Although primarily an antimalarial, it can affect VEGF-B expression in certain immunological contexts. | ||||||